Phase I/II clinical trial of a Wilms‘ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
/in Dendritic Cells, International PublicationsDendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
/in Checkpoint-Inhibitors, Dendritic Cells, International PublicationsCombining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease VirusA randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
/in Colorectal Cancer, Dendritic Cells, International PublicationsRecombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways
/in Dendritic Cells, International Publications, NSCLCAutologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaPhase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsFurther clinical advancement of dendritic cell vaccination against ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerMolecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer